Food, Drugs, Healthcare, Life Sciences

Subscribe
Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.
Article
The Menopause Market Is Becoming Mainstream: What Employers, Providers, And Investors Need To Know Now
The menopause care market is projected to reach tens of billions of dollars by 2030, driven by expanding state coverage mandates and employer benefits. As this frontier in health law and investment accelerates, stakeholders must navigate complex compliance issues spanning telehealth regulations, controlled substances, data privacy, advertising claims, and billing practices across varying state jurisdictions.
United States Healthcare
KM
Katten Muchin Rosenman LLP
Article
The War On Fraud Reaches The States: HHS Defers Medicaid Payments And Expands Exclusion Authority
The Trump administration has announced a major shift in Medicaid fraud enforcement, deferring nearly $1.1 billion in federal payments to California and Minnesota while expanding federal exclusion authority to both CMS and HHS-OIG. This marks a fundamental change from traditional "pay-and-chase" recovery methods to a "prevent and detect" approach that uses data analytics to identify questionable claims before federal funds are disbursed.
United States Healthcare
AP
Arnold & Porter
Article
What The New World Screwworm Response Means For Businesses: Supply Chain Risks And Legal Considerations
The recent resurgence of the New World screwworm (NWS), Cochliomyia hominivorax, has prompted renewed regulatory action by the U.S. Department of Agriculture (USDA) and raised concerns across the livestock industry.NWS is a parasitic fly whose larvae infest open wounds and feed on the living tissue of cattle, wildlife, pets, and other warm-blooded animals, causing serious injury and economic losses.
United States Healthcare
SM
Sheppard, Mullin, Richter & Hampton LLP
See more
Article
The Menopause Market Is Becoming Mainstream: What Employers, Providers, And Investors Need To Know Now
The menopause care market is projected to reach tens of billions of dollars by 2030, driven by expanding state coverage mandates and employer benefits. As this frontier in health law and investment accelerates, stakeholders must navigate complex compliance issues spanning telehealth regulations, controlled substances, data privacy, advertising claims, and billing practices across varying state jurisdictions.
United States Healthcare
KM
Katten Muchin Rosenman LLP
Article
Trump’s Proposed Tariffs On Generic Pharmaceuticals
The Trump Administration has proposed escalating tariffs on imported generic pharmaceuticals, starting at 0% in August 2026 and rising to 200% by 2029, aiming to reshape U.S. pharmaceutical manufacturing and reduce dependence on foreign suppliers. With India supplying a significant portion of America's generic drugs and 91% of U.S. prescriptions being generics, the policy could dramatically impact drug costs, supply chains, and international trade relationships. This trade policy shift reflects the Administ
Worldwide International
TT
Torres Trade Law, PLLC
See more
Article
Ultra-Processed Food Manufacturers Face New Litigation Challenges In California And Beyond
San Francisco's groundbreaking lawsuit against major food manufacturers alleges that ultra-processed foods were engineered to be addictive and deliberately marketed to vulnerable communities while concealing known health risks. This government enforcement action employs public nuisance and unfair competition theories that could fundamentally reshape how packaged foods are regulated, manufactured, and marketed across the United States. Meanwhile, recent federal court decisions reveal the steep causation chal
United States Litigation
GT
Greenberg Traurig, LLP
Article
Trump’s Proposed Tariffs On Generic Pharmaceuticals
The Trump Administration has proposed escalating tariffs on imported generic pharmaceuticals, starting at 0% in August 2026 and rising to 200% by 2029, aiming to reshape U.S. pharmaceutical manufacturing and reduce dependence on foreign suppliers. With India supplying a significant portion of America's generic drugs and 91% of U.S. prescriptions being generics, the policy could dramatically impact drug costs, supply chains, and international trade relationships. This trade policy shift reflects the Administ
Worldwide International
TT
Torres Trade Law, PLLC
Article
Food Regulation Developments: Struggles To Define Ultraprocessed Foods
State legislatures and federal agencies are showing a strong interest in defining and regulating ultraprocessed foods (UPFs), although no uniform definition has emerged. While federal agencies consider whether and how to develop a science-based definition of “ultraprocessed,” states are enacting legislation that directly regulates UPFs or ingredients commonly associated with UPFs.
United States Consumer
BD
Beveridge & Diamond
See more
Article
Formycon And OneSource Specialty Pharma Partner To Manufacture Biosimilars
Formycon AG has announced a strategic manufacturing partnership with OneSource Specialty Pharma Limited to enhance its biosimilar development capabilities. The collaboration brings together Formycon's biosimilar expertise with OneSource's integrated biologics manufacturing platform in Bangalore, India. With three biosimilars already on the U.S. market and four pipeline candidates in development, this partnership aims to strengthen Formycon's position in the competitive biosimilar landscape.
United States Healthcare
GP
Goodwin Procter LLP
See more